Edwards Lifesciences Corp (EW) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) reached $0.67, surpassing Wall Street's consensus estimate of $0.61 by $0.06. Revenue also exceeded expectations, totaling $1.6 billion compared to the anticipated $1.5 billion.
This update provides insight into Edwards Lifesciences' operational performance and financial health. The firm is known for its patient-focused medical innovations in heart disease and critical care monitoring. Based in Irvine, California, it employs approximately 15,800 individuals and has a market capitalization of $47.88 billion.
The company will host an earnings conference call after market close to discuss these results and provide additional commentary on business performance. Investors are encouraged to review the full earnings release and management insights for a comprehensive understanding of the quarter's performance and future outlook.
Looking ahead, Edwards Lifesciences is scheduled to report its next earnings on April 20, 2026, with an EPS estimate of $0.7003 and revenue expectations of $1.6 billion.